Beneficial effect of a chronic treatment with rimonabant on pancreatic function and beta-cell morphology in Zucker Fatty rats
- PMID: 19482020
- DOI: 10.1016/j.ejphar.2009.05.024
Beneficial effect of a chronic treatment with rimonabant on pancreatic function and beta-cell morphology in Zucker Fatty rats
Erratum in
- Eur J Pharmacol. 2009 Oct 25;621(1-3):86
Abstract
Recent studies suggested the involvement of the endocannabinoid pathway on insulin secretion in RINm5F cells or rat islets. Animal and clinical studies have reported beneficial effects of the selective cannabinoid 1 receptor antagonist rimonabant on glucose homeostasis. The aim of this study was to investigate the in vivo effects of rimonabant on pancreatic function in Zucker Fatty rats. Zucker Fatty rats were treated with rimonabant (10 mg kg(-1) day(-1)) or vehicle for up to 3 months. Pancreatic function was assessed by oral glucose tolerance test and by static incubation of islets in the presence of different glucose concentrations. Islet morphology was assessed by immuno-histochemistry on pancreatic sections. After 3 months, there was no difference in fasting glycaemia or AUC(glucose) during oral glucose tolerance test between rimonabant- and vehicle-treated animals. However, vehicle-treated rats developed a marked hyperinsulinaemia with time in contrast to rimonabant-treated animals, which maintained at 3 months significantly lower fasting insulin levels (7.76+/-0.67 microg l(-1) vs. 5.59+/-0.59 microg l(-1), P<0.01) and lower AUC(insulin) (1380+/-98 microg l(-1)min vs. 926+/-58 microg l(-1)min, respectively, P<0.001). In static incubation, rimonabant significantly decreased insulin secretion in response to low glucose concentration (3 months: 7.68+/-1.29 vs. 12.25+/-2.01 microg l(-1) 5 islets(-1) 45 min(-1) in rimonabant and vehicle respectively, P<0.01), resulting in a trend to increase stimulation index in the presence of 16.7 mM glucose (10.64+/-0.92 vs. 8.52+/-1.70 respectively). Morphological analysis at 3 months showed that rimonabant reduced islet-cell surface (-60%) and the percentage of disorganized islets (-54%).In conclusion, our data suggest that rimonabant has a protective role against the development of hyperinsulinaemia, beta-cell dysfunction and islet modification in Zucker Fatty rats.
Similar articles
-
Ibipinabant attenuates β-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight.Diabetes Obes Metab. 2012 Jun;14(6):555-64. doi: 10.1111/j.1463-1326.2012.01563.x. Epub 2012 Feb 24. Diabetes Obes Metab. 2012. PMID: 22268426
-
The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets.Obesity (Silver Spring). 2009 Oct;17(10):1856-60. doi: 10.1038/oby.2009.234. Epub 2009 Jul 30. Obesity (Silver Spring). 2009. PMID: 19644453 Free PMC article.
-
The cannabinoid CB1 receptor and mTORC1 signalling pathways interact to modulate glucose homeostasis in mice.Dis Model Mech. 2016 Jan;9(1):51-61. doi: 10.1242/dmm.020750. Epub 2015 Nov 12. Dis Model Mech. 2016. PMID: 26563389 Free PMC article.
-
The endocannabinoid system and the control of glucose homeostasis.J Neuroendocrinol. 2008 May;20 Suppl 1:147-51. doi: 10.1111/j.1365-2826.2008.01692.x. J Neuroendocrinol. 2008. PMID: 18426514 Review.
-
Metabolic regulation of insulin secretion.Vitam Horm. 2014;95:1-33. doi: 10.1016/B978-0-12-800174-5.00001-6. Vitam Horm. 2014. PMID: 24559912 Review.
Cited by
-
Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.Cell Stress Chaperones. 2016 Jan;21(1):1-7. doi: 10.1007/s12192-015-0653-5. Cell Stress Chaperones. 2016. PMID: 26498013 Free PMC article.
-
Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes.J Control Release. 2023 Jan;353:254-269. doi: 10.1016/j.jconrel.2022.11.040. Epub 2022 Nov 30. J Control Release. 2023. PMID: 36442615 Free PMC article.
-
Endocannabinoid regulation of β-cell functions: implications for glycaemic control and diabetes.Diabetes Obes Metab. 2016 Jun;18(6):549-57. doi: 10.1111/dom.12646. Epub 2016 Mar 31. Diabetes Obes Metab. 2016. PMID: 26880114 Free PMC article. Review.
-
Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels.Am J Physiol Endocrinol Metab. 2012 Mar 1;302(5):E540-51. doi: 10.1152/ajpendo.00250.2011. Epub 2011 Dec 13. Am J Physiol Endocrinol Metab. 2012. PMID: 22167524 Free PMC article.
-
Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice.Mol Cell Endocrinol. 2016 Mar 5;423:1-10. doi: 10.1016/j.mce.2015.12.015. Epub 2015 Dec 25. Mol Cell Endocrinol. 2016. PMID: 26724516 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous